Next-Generation Sequencing Market

The next-generation sequencing market is expected to reach USD 12.45 Billion by 2022 from USD 4.90 Billion in 2017, at a CAGR of 20.5% between 2017 and 2022. Factors such as technological advancements in NGS platforms, increasing applications of NGS, growing partnerships and collaborations, and increasing adoption of NGS among research laboratories and academic institutes are driving the growth of this market. On the other hand, accuracy and standardization concerns in diagnostic testing and the lack of skilled technical personnel are some of the key factors limiting the growth of the market. In addition, storage of sequencing data and interpretation of complex data from NGS platforms are major concerns faced by the sequencing industry.

This report broadly segments the global NGS market into products & services, technology, application, and end user. On the basis of product and service, the NGS market is categorized into pre-sequencing products and services, NGS platforms, consumables, services for platforms, sequencing services, and bioinformatics. In 2017, the consumables segment is expected to account for the largest share of the market.

On the basis of technology, the global NGS market is segmented into sequencing by synthesis (SBS), ion semiconductor sequencing, single-molecule real-time (SMRT) sequencing, and nanopore sequencing. In 2017, the SBS technology is expected to account for the largest share of the market, majorly due to the development of new and advanced NGS platforms, the increasing demand for Illumina’s systems (including the HiSeq series and MiSeq), and the growing demand for NextSeq and HiSeq X Ten.

Based on applications, the market is categorized into six segments, namely, diagnostics, drug discovery, biomarker discovery, precision medicine, agriculture & animal research, and other application. The diagnostics application segment is expected to account for the major share of the global NGS market owing to the increasing focus of key market players on providing & developing NGS-based diagnostic tests and the growing adoption of NGS-based diagnostic tests related to oncology and infectious diseases.

On the basis of end user, the market is segmented into research centers and academic & government institutes, hospitals & clinics, pharmaceutical & biotechnology companies, and other end users. Among these end users, the hospitals and clinics segment is expected to register the highest CAGR due to the growing number of agreements between companies and hospitals for the development of advanced tests and products catering to the specific needs of hospitals and clinics. For instance, in November 2016, Illumina, Inc. entered into an agreement with Mayo Clinic (U.S.) to install its BaseSpace Clarity LIMS in Mayo’s specific laboratories.

Geographically, the market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World (RoW). North America is estimated to command the largest share of the NGS market in 2017, followed by Europe and Asia-Pacific. Emerging markets, like China, India, and Brazil are expected to offer significant growth opportunities owing to the improving healthcare infrastructure, government funding for translational research, and rising partnerships & agreements among market players. In addition, these countries have less-stringent regulations and data requirements as compared to developed nations; companies find regulatory policies in the Asia-Pacific region to be adaptive and business-friendly. Moreover, increasing competition in mature markets will intensify the focus on emerging markets.

The major players in the global market are Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), QIAGEN N. V. (Germany), Pacific Biosciences of California, Inc. (U.S.), BGI (China), Oxford Nanopore Technologies, Ltd. (U.K.), PerkinElmer, Inc. (U.S.), GATC Biotech AG (Germany), Agilent Technologies, Inc. (U.S.), Roche Holding AG (Switzerland), Macrogen, Inc. (South Korea), and Eurofins Scientific (Luxembourg).

As of 2016, Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), and Pacific Biosciences of California, Inc. (U.S.), hold the leading position in the global NGS market. In the past three years, these companies adopted product launches & product enhancements, agreements, collaborations, and partnerships as their key business strategies to ensure market dominance. QIAGEN N. V. (Germany), BGI (China), Oxford Nanopore Technologies, Ltd. (U.K.), PerkinElmer, Inc. (U.S.), GATC Biotech AG (Germany), Agilent Technologies, Inc. (U.S.), Roche Holding AG (Switzerland), Macrogen, Inc. (South Korea), and Eurofins Scientific (Luxembourg) are some of the other major players in this market.